Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00014508

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
CCOP - Northern New Jersey, Hackensack, New Jersey, United States
🇺🇸
Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States

and more 9 locations

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00002792

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Phase 2

Completed

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Blastic Phase
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Disease
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Chronic Phase of Disease

Interventions: Drug: Cyclosporine
Drug: Dasatinib
Drug: Fludarabine Phosphate
Drug: Imatinib Mesylate
Drug: Mycophenolate Mofetil
Drug: Nilotinib
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Allogeneic Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00036738

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Phase 2

Terminated

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 10

Registration Number: NCT00041288

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States

and more 20 locations

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Phase 1

Completed

Conditions: Mycosis Fungoides
Sezary Syndrome

Interventions: Other: A matched peripheral donor stem cells
Drug: cyclosporine
Drug: fludarabine
Drug: Campath

First Posted Date: 2003-01-27

Last Posted Date: 2023-11-14

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 5

Registration Number: NCT00047060

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Lymphoblastic Lymphoma

Interventions: Biological: alemtuzumab
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00040846

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations